Relamorelin
A Phase I clinical trial showed that relamorelin, compared with placebo,
greatly accelerated gastric emptying in patients with diabetic
gastroparesis. Subsequently, a Phase II clinical trial demonstrated that
relamorelin significantly reduced the frequency of vomiting and improved
gastric emptying in patients with diabetic gastroparesis [34]. These
results allowed the FDA to grant a rapid appointment for relamorelin for
the treatment of diabetic gastroparesis in 2016.
The safety and efficacy of relamorelin in chronic constipation were also
assessed. In the Phase II clinical trial, relamorelin significantly
reduced symptoms of constipation and accelerated colonic transit in
female patients with chronic constipation [35]. Also, the same study
showed that relamorelin rapidly increased colonic contractions without
any change in irregular fundus contractions. These promising effects of
relamorelin in gastrointestinal disorders may lead to a wide range of
clinical applications soon [35].